Medication info
Akande Tablet 16 mg (Candesartan Cilexetil)

Akande Tablet 16 mg (Candesartan Cilexetil)

Prescription medicationTabletOral
Ingredient · strength
Candesartan Cilexetil›16mg / 1 tablet
Manufacturer / importer
Hwanin Pharmaceutical Co., Ltd.
Appearance
Light yellow-pink colored tablets with a convex shape on both sides
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201704762 · Approved 2017.06.26 · Insurance code 657203160

Summary

Main use
Treatment of essential hypertension and heart failure with reduced left ventricular systolic function
Who takes it
Adults · Children
Adult dose
Take this medicine at the same time each day, with or without food. 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect occurs within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: In patients at high risk of hypotension, such as those with reduced effective blood volume, administer an initial dose of 4 mg with careful monitoring. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those on hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: The recommended initial dose is 4 mg once daily. Double the dose at intervals of at least 2 weeks, taking the patient's tolerability into account, up to a maximum of 32 mg once daily. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary.
Child dose
1. Essential hypertension 6) Pediatrics: The safety and efficacy have not been established in adolescents and children aged 18 years or younger. 2. Heart failure 3) Pediatrics: The safety and efficacy have not been established in adolescents and children aged 18 years or younger.

Ingredients

Manufacturer
Hwanin Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension and heart failure with reduced left ventricular systolic function

  • Essential hypertension
  • heart failure
  • impaired left ventricular systolic function
  • decreased left ventricular ejection fraction
View approved original text

This medication is used for effectively controlling blood pressure in patients with essential hypertension. It also aids in the treatment of heart failure patients with impaired left ventricular systolic function when additional ACE inhibitors are required or when patients are intolerant to ACE inhibitors. It helps reduce the burden on the heart and alleviates symptoms.

How to take

Adult dose

Take this medicine at the same time each day, with or without food. 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect occurs within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: In patients at high risk of hypotension, such as those with reduced effective blood volume, administer an initial dose of 4 mg with careful monitoring. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those on hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: The recommended initial dose is 4 mg once daily. Double the dose at intervals of at least 2 weeks, taking the patient's tolerability into account, up to a maximum of 32 mg once daily. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary.

Child dose

1. Essential hypertension 6) Pediatrics: The safety and efficacy have not been established in adolescents and children aged 18 years or younger. 2. Heart failure 3) Pediatrics: The safety and efficacy have not been established in adolescents and children aged 18 years or younger.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during pregnancy; thus, it should be discontinued immediately upon confirmation of pregnancy. Patients who are allergic to this drug or the ingredients, pregnant women, lactating women, or those with severe liver dysfunction or cholestasis should not use it. Patients with hereditary angioedema or a history of angioedema with ACE inhibitors or angiotensin II receptor antagonists, and patients with primary hyperaldosteronism should also avoid this medication. Patients with lactose intolerance or specific genetic digestive disorders should not take this drug. Elderly patients, those with hyperkalemia, liver impairment, heart valve disease, ischemic heart disease should be treated cautiously, and care should be taken to prevent blood pressure from dropping too low. Patients with compromised kidney function or those who have recently received a kidney transplant require special monitoring when using this medication. This medication may cause side effects such as dizziness, back pain, respiratory infections, and rare but serious adverse reactions; if any unusual symptoms occur, medical personnel should be informed immediately. Regular monitoring of blood pressure, kidney function, and potassium levels is necessary, especially for heart failure patients or those with renal impairment. When used in combination with other antihypertensive drugs, diuretics, or potassium supplements, the risk of side effects may increase due to drug interactions, so it must be taken as directed by a physician. It is advisable not to use this medication during pregnancy or while breastfeeding, and if breastfeeding, one should stop nursing during treatment. The safety and efficacy in children or adolescents under 18 years of age are not established, and its use is not recommended. When administering to elderly patients, careful adjustment of the dosage is required to prevent excessive blood pressure reduction. In case of overdose, hypotension, dizziness, and tachycardia may occur, and immediate medical attention should be sought for appropriate treatment. This medication should be stored out of reach of children and not transferred to other containers for safety.

Side effects

  • Dizziness
  • low back pain
  • respiratory infections
  • weakness
  • fever
  • sensory disturbances
  • dyspepsia
  • gastritis
  • tachycardia
  • palpitations
Show 66 more
  • increased creatine kinase
  • hyperglycemia
  • hypertriglyceridemia
  • hyperuricemia
  • myalgia
  • epistaxis
  • anxiety
  • depression
  • drowsiness
  • dyspnea
  • rash
  • increased sweating
  • hematuria
  • hypotension
  • hyperkalemia
  • renal impairment
  • increased creatinine
  • increased urea
  • fatigue
  • peripheral edema
  • chest pain
  • headache
  • bronchitis
  • cough
  • sinusitis
  • nausea
  • abdominal pain
  • diarrhea
  • vomiting
  • arthralgia
  • proteinuria
  • leukopenia
  • neutropenia
  • agranulocytosis
  • hyponatremia
  • hypoglycemia
  • intestinal vascular edema
  • increased liver enzyme levels
  • hepatitis
  • elevated AST
  • elevated ALT
  • elevated γ-GTP
  • jaundice
  • urticaria
  • pruritus
  • angioedema
  • rhabdomyolysis
  • acute renal failure
  • interstitial pneumonia
  • shock
  • syncope
  • loss of consciousness
  • paralysis
  • hypertonia
  • facial flushing
  • weight gain
  • facial edema
  • thirst
  • sleep disorders
  • decreased libido
  • forgetfulness
  • loss of appetite
  • increased appetite
  • tinnitus
  • taste disturbance
  • erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it must be stored in a tightly sealed container. It is best to maintain a storage temperature between 1 and 30 degrees Celsius at room temperature to preserve the drug's effectiveness over time.

Appearance and packaging

Appearance

Light yellow-pink colored tablets with a convex shape on both sides

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.